Skip to main content

01.07.2014 | Original Article

qPET – a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma

verfasst von: Dirk Hasenclever, Lars Kurch, Christine Mauz-Körholz, Andreas Elsner, Thomas Georgi, Hamish Wallace, Judith Landman-Parker, Angelina Moryl-Bujakowska, Michaela Cepelová, Jonas Karlén, Ana Álvarez Fernández-Teijeiro, Andishe Attarbaschi, Alexander Fosså, Jane Pears, Andrea Hraskova, Eva Bergsträsser, Auke Beishuizen, Anne Uyttebroeck, Eckhard Schomerus, Osama Sabri, Dieter Körholz, Regine Kluge

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Interim FDG-PET is used for treatment tailoring in lymphoma. Deauville response criteria consist of five ordinal categories based on visual comparison of residual tumor uptake to physiological reference uptakes. However, PET-response is a continuum and visual assessments can be distorted by optical illusions.

Objectives

With a novel semi-automatic quantification tool we eliminate optical illusions and extend the Deauville score to a continuous scale.

Patients and methods

SUVpeak of residual tumors and average uptake of the liver is measured with standardized volumes of interest. The qPET value is the quotient of these measurements. Deauville scores and qPET-values were determined in 898 pediatric Hodgkin’s lymphoma patients after two OEPA chemotherapy cycles.

Results

Deauville categories translate to thresholds on the qPET scale: Categories 3, 4, 5 correspond to qPET values of 0.95, 1.3 and 2.0, respectively. The distribution of qPET values is unimodal with a peak representing metabolically normal responses and a tail of clearly abnormal outliers. In our patients, the peak is at qPET = 0.95 coinciding with the border between Deauville 2 and 3. qPET cut values of 1.3 or 2 (determined by fitting mixture models) select abnormal metabolic responses with high sensitivity, respectively, specificity.

Conclusions

qPET methodology provides semi-automatic quantification for interim FDG-PET response in lymphoma extending ordinal Deauville scoring to a continuous scale. Deauville categories correspond to certain qPET cut values. Thresholds between normal and abnormal response can be derived from the qPET-distribution without need for follow-up data. In our patients, qPET < 1.3 excludes abnormal response with high sensitivity.
Literatur
1.
Zurück zum Zitat Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD 15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–9.PubMedCrossRef Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD 15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–9.PubMedCrossRef
2.
Zurück zum Zitat Gonzalez-Barca E, Canales M, Cortes M, et al. Predictive value of interim 18F-FDG-PET/CT for event free survival in patient with diffus large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first line treatment. Nucl Med Commun. 2013;34:946–52.PubMedCrossRef Gonzalez-Barca E, Canales M, Cortes M, et al. Predictive value of interim 18F-FDG-PET/CT for event free survival in patient with diffus large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first line treatment. Nucl Med Commun. 2013;34:946–52.PubMedCrossRef
3.
Zurück zum Zitat Dührsen U, Hüttmann A, Jöckel KH, et al. Positron emission tomography guided therapy of aggressive non-Hodgkin-lymphomas – the PETAL trial. Leuk Lymphoma. 2009;50:1757–60.PubMedCrossRef Dührsen U, Hüttmann A, Jöckel KH, et al. Positron emission tomography guided therapy of aggressive non-Hodgkin-lymphomas – the PETAL trial. Leuk Lymphoma. 2009;50:1757–60.PubMedCrossRef
4.
Zurück zum Zitat Gallamini A, Patti C, Viviani S, et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with an interim–PET positive after two ABVD courses. Br J Haematol. 2011;152:551–60.PubMedCrossRef Gallamini A, Patti C, Viviani S, et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with an interim–PET positive after two ABVD courses. Br J Haematol. 2011;152:551–60.PubMedCrossRef
5.
Zurück zum Zitat Barrington SF, Mackewn JE, Schleyer P, et al. Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. Ann Oncol. 2011;22:739–45.PubMedCrossRef Barrington SF, Mackewn JE, Schleyer P, et al. Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. Ann Oncol. 2011;22:739–45.PubMedCrossRef
6.
Zurück zum Zitat Körholz D, Kluge R, Wickmann L, et al. Importance of F18-fluorodesxy-D-2-glucose positron emission tomography (FDG-PET) for staging und therapy control of Hodgkin’s lymphoma in childhood and adolescence – consequences for the GPOH-HD 2003 protocol. Onkologie. 2003;26:489–93.PubMedCrossRef Körholz D, Kluge R, Wickmann L, et al. Importance of F18-fluorodesxy-D-2-glucose positron emission tomography (FDG-PET) for staging und therapy control of Hodgkin’s lymphoma in childhood and adolescence – consequences for the GPOH-HD 2003 protocol. Onkologie. 2003;26:489–93.PubMedCrossRef
7.
Zurück zum Zitat Kluge R, Körholz D. Role of FDG-PET in Staging and Therapy of Children with Hodgkin Lymphoma. Klin Padiatr. 2011;223:315–9.PubMedCrossRef Kluge R, Körholz D. Role of FDG-PET in Staging and Therapy of Children with Hodgkin Lymphoma. Klin Padiatr. 2011;223:315–9.PubMedCrossRef
8.
Zurück zum Zitat Kostakoglu L, Gallamini A. Interim 18F-FDG PET in Hodgkin Lymphoma: Would PET-Adapted Clinical Trials Lead to Paradigm Shift? J Nucl Med. 2013;54:1082–93.PubMedCrossRef Kostakoglu L, Gallamini A. Interim 18F-FDG PET in Hodgkin Lymphoma: Would PET-Adapted Clinical Trials Lead to Paradigm Shift? J Nucl Med. 2013;54:1082–93.PubMedCrossRef
9.
Zurück zum Zitat Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performer after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica. 2006;91:475–81.PubMed Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performer after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica. 2006;91:475–81.PubMed
10.
Zurück zum Zitat Meignan M, Gallamini A, Haioun C, et al. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010. Leuk Lymphoma. 2010;51:2171–80.PubMedCrossRef Meignan M, Gallamini A, Haioun C, et al. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010. Leuk Lymphoma. 2010;51:2171–80.PubMedCrossRef
11.
Zurück zum Zitat Bhatia S, Yasui Y, Robison LL. High risk of subsequent neoplasm continues with extended follow up of childhood Hodgkin’s disease: Report from the Late Effects Study Group. J Clin Oncol. 2003;21:4386–94.PubMedCrossRef Bhatia S, Yasui Y, Robison LL. High risk of subsequent neoplasm continues with extended follow up of childhood Hodgkin’s disease: Report from the Late Effects Study Group. J Clin Oncol. 2003;21:4386–94.PubMedCrossRef
12.
Zurück zum Zitat Prasad PK, Signorello LK, Friedman DL, et al. Long term non-cancer mortality in pediatric and young adult cancer survivors in Finland. Pediatr Blood Cancer. 2012;58:421–7.PubMedCentralPubMedCrossRef Prasad PK, Signorello LK, Friedman DL, et al. Long term non-cancer mortality in pediatric and young adult cancer survivors in Finland. Pediatr Blood Cancer. 2012;58:421–7.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer. 2010;55:1145–52.PubMedCrossRef Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer. 2010;55:1145–52.PubMedCrossRef
14.
Zurück zum Zitat Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571–8.PubMedCrossRef Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571–8.PubMedCrossRef
15.
Zurück zum Zitat Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009;50:1257–60.PubMedCrossRef Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009;50:1257–60.PubMedCrossRef
16.
Zurück zum Zitat Gallamini A, Fiore F, Sorasio R, et al. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk Lymphoma. 2009;50:1761–4.PubMedCrossRef Gallamini A, Fiore F, Sorasio R, et al. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk Lymphoma. 2009;50:1761–4.PubMedCrossRef
17.
Zurück zum Zitat Meignan M. Interim PET in lymphoma: a step towards standardization. Eur J Nucl Med Mol Imaging. 2010;37:1821–3.PubMedCrossRef Meignan M. Interim PET in lymphoma: a step towards standardization. Eur J Nucl Med Mol Imaging. 2010;37:1821–3.PubMedCrossRef
18.
Zurück zum Zitat Kurch L, Mauz-Körholz C, Bertling S, et al.: The EuroNet Paediatric Hodgkin Network - Modern imaging data management for real time central review in multicentre trials. Klin Pädiatr. 2013 Epub ahead of print. Kurch L, Mauz-Körholz C, Bertling S, et al.: The EuroNet Paediatric Hodgkin Network - Modern imaging data management for real time central review in multicentre trials. Klin Pädiatr. 2013 Epub ahead of print.
19.
Zurück zum Zitat Keyes JW. SUV: Standard Uptake or Silly Useless Value. J Nucl Med. 1995;35:164–7. Keyes JW. SUV: Standard Uptake or Silly Useless Value. J Nucl Med. 1995;35:164–7.
20.
Zurück zum Zitat Paquet N, Albert A, Foidart J, et al. Within-Patient Variability of 18-F-FDG: Standardized Uptake Values in Normal Tissues. J Nucl Med. 2004;45:784–8.PubMed Paquet N, Albert A, Foidart J, et al. Within-Patient Variability of 18-F-FDG: Standardized Uptake Values in Normal Tissues. J Nucl Med. 2004;45:784–8.PubMed
21.
Zurück zum Zitat Boellaard R, Oyen WJG, Hoekstra CJ, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multicentre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320–33.PubMedCrossRef Boellaard R, Oyen WJG, Hoekstra CJ, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multicentre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320–33.PubMedCrossRef
22.
Zurück zum Zitat Allen-Auerbach M, Weber WA. Measuring Response with FDG-PET: Methodological Aspects. Oncologist. 2009;14:369–77.PubMedCrossRef Allen-Auerbach M, Weber WA. Measuring Response with FDG-PET: Methodological Aspects. Oncologist. 2009;14:369–77.PubMedCrossRef
23.
Zurück zum Zitat Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. J Nucl Med. 2009;50 Suppl 1:122–50.CrossRef Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. J Nucl Med. 2009;50 Suppl 1:122–50.CrossRef
25.
Zurück zum Zitat Boellaard R, O’Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200.PubMedCentralPubMedCrossRef Boellaard R, O’Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Stauss J, Franzius C, Pfluger T, et al. Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging. 2008;35:1581–8.PubMedCrossRef Stauss J, Franzius C, Pfluger T, et al. Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging. 2008;35:1581–8.PubMedCrossRef
27.
Zurück zum Zitat Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885–95.PubMed Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885–95.PubMed
28.
Zurück zum Zitat Horning SJ, Juweid ME, Schöder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115:775–7.PubMedCentralPubMedCrossRef Horning SJ, Juweid ME, Schöder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115:775–7.PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2009;37:1824–33.CrossRef Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2009;37:1824–33.CrossRef
30.
Zurück zum Zitat Furth C, Amthauer H, Hautzel H, et al. Evaluation of interim PET response criteria in paediatric Hodgkin’s lymphoma – results for dedicated assessment criteria in a blinded dual-centre read. Ann Oncol. 2011;22:1198–2003.PubMedCrossRef Furth C, Amthauer H, Hautzel H, et al. Evaluation of interim PET response criteria in paediatric Hodgkin’s lymphoma – results for dedicated assessment criteria in a blinded dual-centre read. Ann Oncol. 2011;22:1198–2003.PubMedCrossRef
31.
Zurück zum Zitat Itti E, Meignan M, Berriolo-Riedinger A, et al. An International confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and delta-SUVmax. Eur J Nucl Med Mol Imaging. 2013;40:1312–20.PubMedCrossRef Itti E, Meignan M, Berriolo-Riedinger A, et al. An International confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and delta-SUVmax. Eur J Nucl Med Mol Imaging. 2013;40:1312–20.PubMedCrossRef
33.
Zurück zum Zitat Meignan M, Barrington S, Itti E, et al.: Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3–5 October 2012. Leuk Lymphoma. 2014;55:31–7. Meignan M, Barrington S, Itti E, et al.: Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3–5 October 2012. Leuk Lymphoma. 2014;55:31–7.
34.
Zurück zum Zitat Ilivitzke A, Radan L, Ben-Arush M, et al. Early interim FDG PET/CT prediction of treatment response and prognosis in pediatric Hodgkin disease-added value of low dose CT. Pediatr Radiol. 2013;43:86–92.CrossRef Ilivitzke A, Radan L, Ben-Arush M, et al. Early interim FDG PET/CT prediction of treatment response and prognosis in pediatric Hodgkin disease-added value of low dose CT. Pediatr Radiol. 2013;43:86–92.CrossRef
35.
Zurück zum Zitat Furth C, Steffen IG, Amthauer H, et al. Early and Late Therapy Response Assessment with [18F]Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin’s Lymphoma: Analysis of a Prospective Multicenter Trial. J Clin Oncol. 2013;27:4385–91.CrossRef Furth C, Steffen IG, Amthauer H, et al. Early and Late Therapy Response Assessment with [18F]Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin’s Lymphoma: Analysis of a Prospective Multicenter Trial. J Clin Oncol. 2013;27:4385–91.CrossRef
36.
Zurück zum Zitat Cerci JJ, Pracchia LF, Linardi CCG, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin Lymphoma. JNM. 2010;51:1337–43.PubMedCrossRef Cerci JJ, Pracchia LF, Linardi CCG, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin Lymphoma. JNM. 2010;51:1337–43.PubMedCrossRef
37.
Zurück zum Zitat Gallamini A, Hutchings M, Rigacci L, et al. Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography is prognostically superior to International Prognosic Score in Advanced-Stage Hodgkin’s Lymphoma: A Report from a joint Italian-Danish Study. J Clin Oncol. 2007;25:3746–52.PubMedCrossRef Gallamini A, Hutchings M, Rigacci L, et al. Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography is prognostically superior to International Prognosic Score in Advanced-Stage Hodgkin’s Lymphoma: A Report from a joint Italian-Danish Study. J Clin Oncol. 2007;25:3746–52.PubMedCrossRef
38.
Zurück zum Zitat Cashen AF, Dehdashti F, Luo J, et al. 18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation. J Clin Oncol. 2011;52:386–92. Cashen AF, Dehdashti F, Luo J, et al. 18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation. J Clin Oncol. 2011;52:386–92.
39.
Zurück zum Zitat Le Roux PY, Gastinne T, Le Gouill S, et al. Prognostic value of interim FDG PET/CT in Hodgkin’s lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging. 2011;38:1064–71.PubMedCrossRef Le Roux PY, Gastinne T, Le Gouill S, et al. Prognostic value of interim FDG PET/CT in Hodgkin’s lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging. 2011;38:1064–71.PubMedCrossRef
40.
Zurück zum Zitat Manohar K, Mittal BR, Raja S, et al. Comparison of various criteria in interpreting end of therapy F-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography in patients with aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2013;54:714–9.PubMedCrossRef Manohar K, Mittal BR, Raja S, et al. Comparison of various criteria in interpreting end of therapy F-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography in patients with aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2013;54:714–9.PubMedCrossRef
Metadaten
Titel
qPET – a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma
verfasst von
Dirk Hasenclever
Lars Kurch
Christine Mauz-Körholz
Andreas Elsner
Thomas Georgi
Hamish Wallace
Judith Landman-Parker
Angelina Moryl-Bujakowska
Michaela Cepelová
Jonas Karlén
Ana Álvarez Fernández-Teijeiro
Andishe Attarbaschi
Alexander Fosså
Jane Pears
Andrea Hraskova
Eva Bergsträsser
Auke Beishuizen
Anne Uyttebroeck
Eckhard Schomerus
Osama Sabri
Dieter Körholz
Regine Kluge
Publikationsdatum
01.07.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2014
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-014-2715-9